Header Logo

Connection

Jinal Bhiman to Humans

Back to Details
This is a "connection" page, showing publications Jinal Bhiman has written about Humans.
Jinal Bhiman
Connection Strength
0,983
Humans
  1. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages. Sci Rep. 2023 01 21; 13(1):1222.
    View in: PubMed
    Score: 0,065
  2. Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. Nat Commun. 2022 04 08; 13(1):1976.
    View in: PubMed
    Score: 0,062
  3. Size Doesn't Matter: Shorter Antibody Loops Can Infiltrate HIV's Env Apex Defenses. Immunity. 2017 05 16; 46(5):762-764.
    View in: PubMed
    Score: 0,044
  4. Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System. Curr HIV/AIDS Rep. 2017 04; 14(2):54-62.
    View in: PubMed
    Score: 0,044
  5. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015 Nov; 21(11):1332-6.
    View in: PubMed
    Score: 0,040
  6. Rapid intra-host diversification and evolution of SARS-CoV-2 in advanced HIV infection. Nat Commun. 2024 Aug 22; 15(1):7240.
    View in: PubMed
    Score: 0,018
  7. Standardized Phylogenetic Classification of Human Respiratory Syncytial Virus below the Subgroup Level. Emerg Infect Dis. 2024 Aug; 30(8):1631-1641.
    View in: PubMed
    Score: 0,018
  8. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive Fc?RIIIa signaling and neutralization than BA.1, in the context of hybrid immunity. J Virol. 2024 Jul 23; 98(7):e0067824.
    View in: PubMed
    Score: 0,018
  9. SARS-CoV-2 humoral immunity in people living with HIV-1. Trends Immunol. 2024 Jul; 45(7):511-522.
    View in: PubMed
    Score: 0,018
  10. Characteristics of infections with ancestral, Beta and Delta variants of SARS-CoV-2 in the PHIRST-C community cohort study, South Africa, 2020-2021. BMC Infect Dis. 2024 Mar 21; 24(1):336.
    View in: PubMed
    Score: 0,018
  11. SARS-CoV-2 genomic surveillance in wastewater as a model for monitoring evolution of endemic viruses. Nat Commun. 2023 10 10; 14(1):6325.
    View in: PubMed
    Score: 0,017
  12. Healthcare utilization during the first two waves of the COVID-19 epidemic in South Africa: A cross-sectional household survey. PLoS One. 2023; 18(8):e0290787.
    View in: PubMed
    Score: 0,017
  13. Knowledge, attitudes, practices and intention to get vaccinated against COVID-19: results from a cross-sectional survey in three peri-urban communities in South Africa. Pan Afr Med J. 2023; 45:120.
    View in: PubMed
    Score: 0,017
  14. Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005). Vaccine. 2023 05 26; 41(23):3486-3492.
    View in: PubMed
    Score: 0,017
  15. Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From Adult Index Cases With and Without Human Immunodeficiency Virus in South Africa, 2020-2021: A Case-Ascertained, Prospective, Observational Household Transmission Study. Clin Infect Dis. 2023 02 08; 76(3):e71-e81.
    View in: PubMed
    Score: 0,016
  16. Results from the second WHO external quality assessment for the molecular detection of respiratory syncytial virus, 2019-2020. Influenza Other Respir Viruses. 2023 01; 17(1):e13073.
    View in: PubMed
    Score: 0,016
  17. Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa. Nat Commun. 2023 01 16; 14(1):246.
    View in: PubMed
    Score: 0,016
  18. High prevalence of SARS-CoV-2 antibodies in pregnant women after the second wave of infections in the inner-city of Johannesburg, Gauteng Province, South Africa. Int J Infect Dis. 2022 Dec; 125:241-249.
    View in: PubMed
    Score: 0,016
  19. The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance. Science. 2022 10 07; 378(6615):eabq5358.
    View in: PubMed
    Score: 0,016
  20. Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. Nat Commun. 2022 10 04; 13(1):5860.
    View in: PubMed
    Score: 0,016
  21. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022 09; 28(9):1785-1790.
    View in: PubMed
    Score: 0,016
  22. Selection Analysis Identifies Clusters of Unusual Mutational Changes in Omicron Lineage BA.1 That Likely Impact Spike Function. Mol Biol Evol. 2022 Apr 11; 39(4).
    View in: PubMed
    Score: 0,016
  23. SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa. Emerg Infect Dis. 2022 May; 28(5):1055-1058.
    View in: PubMed
    Score: 0,015
  24. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21. Lancet Infect Dis. 2022 Jun; 22(6):821-834.
    View in: PubMed
    Score: 0,015
  25. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Sci Rep. 2022 02 15; 12(1):2552.
    View in: PubMed
    Score: 0,015
  26. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature. 2022 03; 603(7901):488-492.
    View in: PubMed
    Score: 0,015
  27. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022 01 29; 399(10323):437-446.
    View in: PubMed
    Score: 0,015
  28. Reduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests. J Virol Methods. 2022 04; 302:114471.
    View in: PubMed
    Score: 0,015
  29. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022 03; 603(7902):679-686.
    View in: PubMed
    Score: 0,015
  30. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022 02; 602(7898):654-656.
    View in: PubMed
    Score: 0,015
  31. A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. Science. 2021 Oct 22; 374(6566):423-431.
    View in: PubMed
    Score: 0,015
  32. SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021. Emerg Infect Dis. 2021 12; 27(12):3020-3029.
    View in: PubMed
    Score: 0,015
  33. Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nat Commun. 2021 08 10; 12(1):4817.
    View in: PubMed
    Score: 0,015
  34. Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. Lancet Glob Health. 2021 09; 9(9):e1216-e1225.
    View in: PubMed
    Score: 0,015
  35. SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. Nat Microbiol. 2021 07; 6(7):821-823.
    View in: PubMed
    Score: 0,015
  36. Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020. Euro Surveill. 2021 07; 26(29).
    View in: PubMed
    Score: 0,015
  37. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med. 2021 06 03; 384(22):2161-2163.
    View in: PubMed
    Score: 0,014
  38. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 05 20; 384(20):1885-1898.
    View in: PubMed
    Score: 0,014
  39. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021 04; 592(7854):438-443.
    View in: PubMed
    Score: 0,014
  40. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021 04; 27(4):622-625.
    View in: PubMed
    Score: 0,014
  41. Sixteen novel lineages of SARS-CoV-2 in South Africa. Nat Med. 2021 03; 27(3):440-446.
    View in: PubMed
    Score: 0,014
  42. COVID-19 testing in Africa: lessons learnt. Lancet Microbe. 2020 07; 1(3):e103-e104.
    View in: PubMed
    Score: 0,014
  43. Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications. Sci Rep. 2020 04 10; 10(1):6201.
    View in: PubMed
    Score: 0,013
  44. Rapid Germinal Center and Antibody Responses in Non-human Primates after a Single Nanoparticle Vaccine Immunization. Cell Rep. 2019 11 12; 29(7):1756-1766.e8.
    View in: PubMed
    Score: 0,013
  45. Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. PLoS Pathog. 2019 09; 15(9):e1008005.
    View in: PubMed
    Score: 0,013
  46. V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. Cell Rep. 2018 12 11; 25(11):3123-3135.e6.
    View in: PubMed
    Score: 0,012
  47. Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. Nat Commun. 2018 10 08; 9(1):4136.
    View in: PubMed
    Score: 0,012
  48. HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Cell Host Microbe. 2018 10 10; 24(4):593-599.e3.
    View in: PubMed
    Score: 0,012
  49. Strategies for a multi-stage neutralizing antibody-based HIV vaccine. Curr Opin Immunol. 2018 08; 53:143-151.
    View in: PubMed
    Score: 0,012
  50. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
    View in: PubMed
    Score: 0,011
  51. Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Rep. 2016 Jan 05; 14(1):43-54.
    View in: PubMed
    Score: 0,010
  52. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2016 01 01; 90(1):76-91.
    View in: PubMed
    Score: 0,010
  53. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 01; 509(7498):55-62.
    View in: PubMed
    Score: 0,009
  54. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013 Oct; 9(10):e1003738.
    View in: PubMed
    Score: 0,009
  55. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92.
    View in: PubMed
    Score: 0,008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.